Xenon xe-133 - Generic Drug Details

What are the generic sources for xenon xe-133 and what is the scope of freedom to operate?

Xenon xe-133 is the generic ingredient in three branded drugs marketed by Curium, Ge Healthcare, Gen Electric, Lantheus Medcl, and Mallinckrodt, and is included in seven NDAs. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for xenon xe-133. Two suppliers are listed for this compound.

Summary for xenon xe-133

US Patents:	0
Tradenames:	3
Applicants:	5
NDAs:	7
Drug Master File Entries:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	7
Patent Applications:	618
What excipients (inactive ingredients) are in xenon xe-133?	xenon xe-133 excipients list
DailyMed Link:	xenon xe-133 at DailyMed

Pharmacology for xenon xe-133

Drug Class	Inhalation Diagnostic Agent
Mechanism of Action	Radiopharmaceutical Activity

Anatomical Therapeutic Chemical (ATC) Classes for xenon xe-133

N01AX	Other general anesthetics
N01A	ANESTHETICS, GENERAL
N01	ANESTHETICS
N	Nervous system

US Patents and Regulatory Information for xenon xe-133

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gen Electric	XENON XE 133	xenon xe-133	GAS;INHALATION	017550-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Mallinckrodt	XENEISOL	xenon xe-133	SOLUTION;INHALATION, INJECTION	017262-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Curium	XENON XE 133	xenon xe-133	GAS;INHALATION	018327-002	Mar 9, 1982		RX	No	No
Ge Healthcare	XENON XE 133	xenon xe-133	GAS;INHALATION	017256-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Lantheus Medcl	XENON XE 133	xenon xe-133	INJECTABLE;INJECTION	017283-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Ge Healthcare	XENON XE 133-V.S.S.	xenon xe-133	GAS;INHALATION	017687-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Xenon xe-133 Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Xenon Xe-133

Introduction

Xenon Xe-133 is a radiopharmaceutical imaging agent used primarily for the evaluation of pulmonary function and imaging the lungs. It also has applications in assessing cerebral blood flow. Here, we delve into the market dynamics and financial trajectory of Xenon Xe-133, highlighting its current status, growth prospects, and key factors influencing its market.

Market Size and Growth

The global market for xenon, which includes Xenon Xe-133, was valued at USD 253.14 million in 2023. This market is projected to grow to USD 304.74 million by 2032, exhibiting a Compound Annual Growth Rate (CAGR) of 2.1% during the forecast period[1].

Key Applications

Xenon Xe-133 is primarily used in medical imaging, particularly for:

Pulmonary Function Evaluation

Inhalation of Xenon Xe-133 has proven valuable for assessing lung function and imaging the lungs. It is used to evaluate ventilation and perfusion in the lungs, providing critical diagnostic information[2][3].

Cerebral Blood Flow Assessment

Xenon Xe-133 can also be used to assess cerebral blood flow, which is essential in diagnosing and managing cerebrovascular diseases[2][4].

Market Segmentation

The xenon market, including Xenon Xe-133, is segmented into several applications:

Imaging & Lighting

Although this segment is shrinking due to the increasing adoption of LED technology, Xenon Xe-133 remains relevant in medical imaging[1].

Medical

This segment is a significant driver for Xenon Xe-133, given its use in pulmonary and cerebral imaging. The medical application is expected to maintain a steady demand due to its diagnostic value[2][3].

Satellite and Electronics

While these segments are more relevant to non-radioactive xenon, they contribute to the overall market dynamics and demand for xenon, indirectly influencing the availability and pricing of Xenon Xe-133[1].

Regional Market Analysis

Asia Pacific

Asia Pacific dominates the xenon market, with a significant share attributed to the rising demand from the satellite industry and other applications. Countries like China and Japan are major consumers of xenon for satellite and semiconductor applications[1].

United States

The U.S. market for xenon is expected to grow significantly, driven by robust adoption in satellites and imaging & lighting applications. The market size in the U.S. is projected to reach an estimated value of USD 71.42 million by 2032[1].

Europe

Europe is expected to witness moderate growth, driven by demand from semiconductor and satellite applications. Ongoing research, such as dark matter studies in Italy, also contributes to the regional demand[1].

Latin America and Middle East & Africa

These regions are expected to show lower market value growth due to fewer developments in the end-use markets. The demand here is primarily driven by lighting and imaging applications[1].

Supply and Distribution

Lantheus Holdings is a key player in the supply of Xenon Xe-133, ensuring a continuous and secure supply to the U.S. medical market. The company has partnered with the Institute for Radioelements (IRE) to secure this supply[3].

Safety and Handling

Xenon Xe-133 must be handled with care due to its radioactive nature. It is supplied in vials as part of the Calidose™ system, and specific safety measures are required to minimize radiation exposure to patients and clinical personnel[2][3].

Financial Trajectory

The financial trajectory of Xenon Xe-133 is closely tied to the overall xenon market. Here are some key financial indicators:

Market Value

The global xenon market, which includes Xenon Xe-133, is projected to grow from USD 258.74 million in 2024 to USD 304.74 million by 2032[1].

Revenue Growth

The CAGR of 2.1% during the forecast period indicates steady growth, driven primarily by medical and satellite applications[1].

Regional Revenue

Asia Pacific and the U.S. are expected to be significant contributors to the revenue growth, with the U.S. market projected to reach USD 71.42 million by 2032[1].

Key Takeaways

• Market Growth: The global xenon market, including Xenon Xe-133, is expected to grow at a CAGR of 2.1% from 2024 to 2032.
• Medical Applications: Xenon Xe-133 is crucial for pulmonary function evaluation and cerebral blood flow assessment.
• Regional Dominance: Asia Pacific and the U.S. are key regions driving the market growth.
• Supply Security: Lantheus Holdings ensures a continuous supply of Xenon Xe-133 to the U.S. medical market.
• Safety and Handling: Strict safety measures are necessary due to the radioactive nature of Xenon Xe-133.

FAQs

What are the primary applications of Xenon Xe-133?

Xenon Xe-133 is primarily used for the evaluation of pulmonary function and imaging the lungs, as well as assessing cerebral blood flow.

Who are the key suppliers of Xenon Xe-133?

Lantheus Holdings is a leading supplier of Xenon Xe-133, partnering with the Institute for Radioelements (IRE) to ensure a continuous supply.

What is the projected market size of Xenon Xe-133 by 2032?

The global xenon market, which includes Xenon Xe-133, is projected to reach USD 304.74 million by 2032.

What are the safety precautions for handling Xenon Xe-133?

Xenon Xe-133 must be handled with care to minimize radiation exposure. It should be used only by qualified physicians and handled according to specific safety protocols.

How does the regional market impact the demand for Xenon Xe-133?

Asia Pacific and the U.S. are significant regions driving the demand for Xenon Xe-133, with Asia Pacific dominating the market due to its satellite and semiconductor industries.

Sources

1. Fortune Business Insights: Xenon Market Size, Growth | Industry Share & Forecast [2032]
2. Journal of Nuclear Medicine: Lantheus Xenon Xe-133 Gas
3. Lantheus Holdings: Lantheus Holdings Announces First Commercial Shipment of Xenon 133
4. Science.gov: Xenon-133 inhalation method: Topics by Science.gov
5. Copernicus.org: Xenon-133 and caesium-137 releases into the atmosphere from the Fukushima Dai-ichi nuclear power plant